Unorthodox routes to prostanoid formation: New twists in cyclooxygenase-initiated pathways

Journal of Clinical Investigation

Volumn 107, Issue 12, 2001, Pages 1481-1489

  Serhan, C N ^a   Oliw, E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FATTY ACID; FISH OIL; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN H; PROSTAGLANDIN SYNTHASE; PROSTANOID;

ACETYLATION; AUTOOXIDATION; BIOSYNTHESIS; ENZYME METABOLISM; HUMAN; INFLAMMATION; PRIORITY JOURNAL; REVIEW; SEMINAL PLASMA;

EID: 0034978980     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI13375     Document Type: Review

References (71)

1. On the specific vaso dilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin)
2. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions
3. Novel functional arrays of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing
4. Identification of CYP4F8 in human seminal vesicles as a prominent 19- hydroxylase of prostaglandin endoperoxides
5. The prostaglandins: From the laboratory to the clinic
6. From studies of biochemical mechanisms to novel biological mediators: Prostaglandin endoperoxides, thromboxanes and leukotrienes
7. Adventures and excursions in bioassay: The stepping stones to prostacyclin
8. On the incorporation of oxygen in the conversion of 8,11,14-eicosatrienoic acid to prostaglandin E1
9. Spatial requirements for 15-(R)-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid synthesis within the cyclooxygenase active site of murine COX-2
10. The productive conformation of arachidonic acid bound to prostaglandin synthase
11. Regulated formation of eicosanoids
12. Analysis of hydroperoxide-induced tyrosyl radicals and lipoxygenase activity in aspirin-treated human prostaglandin H synthase-2
13. Oxygenation of 5,8,11-eicosatrienoic acid by prostaglandin endoperoxide synthase and by cytochrome P450 monooxygenase: Structure and mechanism of formation of major metabolites
14. Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2
15. Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2
16. Recent progress in the cellular and molecular biology of prostaglandin synthesis
17. Why there are two cyclooxygenase isozymes
18. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines
19. Cyclooxygenase-selective inhibition of prostanoid formation: Transducing biochemical selectivity into clinical read-outs
20. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial
21. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
22. Cyclooxygenase-2 enzyme inhibitors: Place in therapy
23. Cyclooxygenase-2-specific inhibitors: Are they safe?
24. 19-Hydroxylated E prostaglandins as the major prostaglandins of human semen
25. Rapid and slow hydroxylators of seminal E prostaglandins
26. Genetic and pharmacological analysis of prostanoid receptor function
27. Mixed messages: Modulation of inflammation and immune responses by prostaglandins and thromboxanes
28. Identification of 19 (R)-OH prostaglandin E2 as a selective prostanoid EP2-receptor agonist
29. The action of prostaglandin E2 on the human cervix: Stimulation of interleukin 8 and inhibition of secretory leukocyte protease inhibitor
30. Identification of human prostaglandin E synthase: A microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target
31. Mechanisms of free radical oxidation of unsaturated lipids
32. Isoprostanes: Formation, analysis and use as indices of lipid peroxidation in vivo
33. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo
34. The isoprostanes: Their quantification as an index of oxidant stress status in vivo
35. IPF2alpha-I: An index of lipid peroxidation in humans
36. Identification of two major F2 isoprostanes, 8,12-iso-and 5-epi-8, 12-iso-isoprostane F2alpha-VI, in human urine
37. Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F(2)-isoprostanes in human urine
38. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation
39. Alcohol-induced generation of lipid petoxidation products in humans
40. Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E
41. Prostaglandin F2alpha (PGF2alpha) and the isoprostane, 8, 12-iso-isoprostane F2alpha-III, induce cardiomyocyte hypertrophy. Differential activation of downstream signaling pathways
42. Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets
43. Cytochromes P450 wire bisallylic hydroxylation activity on arachidonic and linoleic acids studied with human recombinant enzymes and with human and rat liver microsomes
44. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase
45. Metabolism of 5(6)oxidoeicosatrienoic acid by ram seminal vesicles. Formation of two stereoisomers of 5-hydroxyprostaglandin 11
46. Metabolism of 5,6-epoxyeicosatrienoic acid by the human platelet. Formation of novel thromboxane analogs
47. Renal vasodilator activity of 5,6-epoxyeicosatrienoic acid depends upon conversion by cyclooxygenase and release of prostaglandins
48. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFκB
49. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
50. 4 stable analogs that block transmigration and adhesion of human neutrophils
51. 4 analogs
52. Altered sensitivity of aspirin-acetylated prostaglandin G/H synthase-2 inhibition by nonsteroidal anti-inflammatory drugs
53. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
54. Aspirin-like molecules that covalently inactivate cyclooxygenase-2
55. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): A jungle of cell-cell interactions or a therapeutic opportunity?
56. 4 ELISA
57. Platelets: Their role in hemostasis, thrombosis, and inflammation
58. Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with cirrhosis and ascites
59. Lipoxins and other arachidonate derived mediators in bronchial asthma
60. 4 receptor
61. 4 and regulation of vascular and inflammatory responses
62. Workshop on the essentiality of an recommended dietary intakes for omega-6 and omega-3 fatty acids
63. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial
64. Trout thrombocytes contain 12- but not 5-lipoxygenase activity
65. Prevention of sudden cardiac death by dietary pure ω-3 polyunsaturated fatty acids in dogs
66. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo
67. Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis
68. COX-2 inhibitors
69. Cutting edge: Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages
70. 4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases